<DOC>
	<DOCNO>NCT01514123</DOCNO>
	<brief_summary>This non-randomized , multi-dose , first-in-human , multicenter , two arm ( Arm A : VGX-100 alone ; Arm B : VGX-100 co-administered bevacizumab ) , open label , dose escalation study subject advance metastatic solid tumor . The study aim evaluate safety establish recommend dose VEGF-C human monoclonal antibody VGX-100 administer alone combination bevacizumab .</brief_summary>
	<brief_title>Study VGX-100 Administered Alone Co-administered With Bevacizumab Adult Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<criteria>Age ≥ 18 year Provision write informed consent Histologically cytologically document advanced metastatic solid tumor refractory standard treatment , standard therapy available , subject refuse standard therapy Life expectancy &gt; 3 month opinion investigator ECOG performance status 0 1 Evaluable OR measurable disease RECIST 1.1 criterion Agree use effective contraceptive either male female child bear potential Inadequate venous access Women lactating/breastfeeding Women positive pregnancy test planning become pregnant duration study Known HIV positive , chronic hepatitis B C Major surgical procedure within 6 week Baseline surgical wound fully heal Baseline Untreated symptomatic brain metastasis , know central nervous system metastasis , spinal cord compression ( except glioblastoma multiforme ) Mediastinal cavitated , lung mass locate near , invade encase major blood vessel airway image Squamous cell lung cancer History known/suspected gastrointestinal perforation Hemoptysis &gt; 2.5 mL ( half teaspoon ) red blood within 28 day Screening Deep venous thrombosis history symptomatic pulmonary thromboembolism within 6 month Screening Gastrointestinal bleeding require medical intervention within 28 day Screening Receipt therapeutic concentration warfarin anticoagulant within 7 day Screening Receipt investigational agent ( ) indication within 28 day Baseline 5 half life , whichever great Receipt follow treatment : Traditional cytotoxics , tyrosine kinase inhibitor small molecule anticancer agent within 21 day Nitrosoureas , mitomycin C , bevacizumab trastuzumab within 6 week Any therapeutic monoclonal antibody within 21 day Hormonal therapy ( gonadal suppression ) within 14 day Radiotherapy : &gt; 25 % bone marrow brain within 28 day baseline within 14 day baseline Unstable angina , myocardial infarction , transient ischemic event , stroke within 24 week Screening History CNS hemorrhage , cerebrovascular hemorrhage , myocardial infarction reversible posterior leukoencephalopathy syndrome associate prior antiVEGF/antiVEGFR therapy Uncontrolled hypertension ≥ CTCAE Grade 2 Proteinuria Baseline ≥2+ 1.0g/24 hour Prior allergic reaction monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>VGX-100</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>VEGF-C</keyword>
	<keyword>First-In-Human</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Oncology</keyword>
	<keyword>Advanced malignancy</keyword>
</DOC>